Stragen
Joan Nilsson has extensive experience in the pharmaceutical industry, currently serving as Market Access Manager at GSK since November 2016 and Nordic Sales and Tender Manager at Stragen since April 2015. Previous roles include Market Access Manager at Sandoz, focusing on respiratory treatments in Denmark, and Key Account Manager at Ferring Pharmaceuticals, where responsibilities encompassed fertility treatment and supporting medical projects. Earlier in their career, Joan held positions at ALK Abelló as Area Manager for allergy and asthma treatments, MSD as a Product Specialist in primary care and gynecology, and at Leo Pharmaceuticals in research and development. Joan began foundational work in pharmacy at Trøjborg Apotek and holds a Bachelor of Pharmacy degree from Pharmakon, along with a Medical Market Access Diploma from Medicademy.
This person is not in any offices
Stragen
Focusing on innovation for health solutions since 1990, Stragen is a global player in the development, registration and distribution of Generic drugs and Consumer Health products. Starting as a small API trading platform 30 years ago in Geneva, Switzerland, today Stragen operates in over 60 markets through a network of dynamic and collaborative partners, employing over 150 people and working with 10 dedicated affiliates worldwide. As a result of decades of experience and expertise in R&D, combined with our continuous commitment to advancing public health, we invest in the fundamental research through to the delivery of innovative and trusted health solutions to address unmet medical needs. We focus on two core activities: • Selected and Advanced Generics • Consumer Health products Our specialized and passionate scientific team consistently operates under the latest quality standards to deliver Swiss tailor-made solutions with the final product 100% manufactured in Europe. At Stragen, we understand that business models need to be reinvented to work within our competitive and fast-changing environment of the Pharma industry. We have identified how we can positively diversify our activities beyond the historical development and licensing out of Generic+ products, to the development of Consumer Health products as well as the development through to proof of concept of patented new drugs.